<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052127</url>
  </required_header>
  <id_info>
    <org_study_id>AU-011-101</org_study_id>
    <nct_id>NCT03052127</nct_id>
  </id_info>
  <brief_title>Study in Subjects With Small Primary Choroidal Melanoma</brief_title>
  <official_title>A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aura Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aura Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety, immunogenicity and efficacy of one of three
      dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser
      applications for the treatment of subjects with primary choroidal melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to
      evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with
      small primary choroidal melanoma.

      Throughout the study, subjects will be monitored through medical and ophthalmic assessments.
      Subjects will be followed for a total of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011</measure>
    <time_frame>Informed consent through 2 years</time_frame>
    <description>Adverse events will be summarized by presenting the number and percentage of patients having any adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Screening to various time points through Week 52</time_frame>
    <description>Anti-Drug Antibody analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor size (thickness) measured by ultrasonography [Efficacy]</measure>
    <time_frame>Change from baseline at 3 months following treatment and at each subsequent visit through study completion (2 years)</time_frame>
    <description>Tumor size (thickness) measured by ultrasonography (millimeters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor size (diameter) measured by fundus photography [Efficacy]</measure>
    <time_frame>Change from baseline at 3 months following treatment and at each subsequent visit through study completion (2 years)</time_frame>
    <description>Tumor size (diameter) measured by fundus photography (millimeters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity measured by ETDRS Method [Efficacy]</measure>
    <time_frame>Change from baseline at 3 months following treatment and at each subsequent visit through study completion (2 years)</time_frame>
    <description>Changes in ETDRS best corrected visual acuity (BCVA)</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Ocular Melanoma</condition>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>Single Low Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Light-activated AU-011 followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Medium Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose Light-activated AU-011 followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single High Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Light-activated AU-011 followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Repeat Medium Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Repeat Medium Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 repeat medium doses of Light-activated AU-011 followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Light-activated AU-011 followed by two laser light applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Repeat High Dose Light-activated AU-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 repeat high doses of Light-activated AU-011 each followed by a single laser light application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Repeat High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 repeat high doses of Light-activated AU-011 each followed by two laser light applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation until Documented Growth of Tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Light-activated AU-011</intervention_name>
    <description>Study treatment</description>
    <arm_group_label>2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers</arm_group_label>
    <arm_group_label>2 Repeat Medium Dose Light-activated AU-011</arm_group_label>
    <arm_group_label>3 Repeat High Dose Light-activated AU-011</arm_group_label>
    <arm_group_label>3 Repeat High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_label>3 Repeat Medium Dose Light-activated AU-011</arm_group_label>
    <arm_group_label>Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers</arm_group_label>
    <arm_group_label>Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_label>Observation until Documented Growth of Tumor</arm_group_label>
    <arm_group_label>Single High Dose Light-activated AU-011</arm_group_label>
    <arm_group_label>Single High Dose Light-activated AU-011 x 2 lasers</arm_group_label>
    <arm_group_label>Single Low Dose Light-activated AU-011</arm_group_label>
    <arm_group_label>Single Medium Dose Light-activated AU-011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of choroidal melanoma

        Exclusion Criteria:

          -  Have known contraindications or sensitivities to the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijit Narvekar, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Aura Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Associates SW, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. K. Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Carolina, PA</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveal melanoma</keyword>
  <keyword>Eye cancer</keyword>
  <keyword>Ocular melanoma</keyword>
  <keyword>Choroidal melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

